Quality of life and tolerability in patients with schizophrenia taking atypical antipsychotics

被引：10
|
作者：
Fleming, K. [1 ]
Potkin, S. G. [1 ]
Binneman, B. [2 ]
Keller, D. [3 ]
Alphs, L. [4 ]
Panagides, J.
机构：
[1] Univ Calif Irvine, Dept Psychiat, Irvine, CA 92717 USA
[2] Pfizer Inc, Clin R&D, Groton, CT USA
[3] Pfizer Inc, Clin Pharmacol & Stat, Groton, CT USA
[4] Pfizer Inc, Global R&D, Ann Arbor, MI USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2007年 / 17卷
关键词：
D O I：
10.1016/S0924-977X(07)70710-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S466 / S467
页数：2
相关论文
共 50 条
  • [31] New antipsychotics, compliance, quality of life, and subjective tolerability - Are patients better off?
    Awad, AG
    Voruganti, LNP
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2004, 49 (05): : 297 - 302
  • [32] Tolerability: A pharmacological rationale for atypical antipsychotics
    Tauscher, J
    EUROPEAN PSYCHIATRY, 2004, 19 : 145S - 145S
  • [33] Metabolic syndrome in patients with schizophrenia receiving atypical antipsychotics
    Kornetova, E.
    Kornetov, A.
    Dubrovskaya, V.
    Arzhanik, M.
    Ivanova, S.
    EUROPEAN PSYCHIATRY, 2019, 56 : S273 - S273
  • [34] Switching to aripiprazole from atypical antipsychotics in patients with schizophrenia
    Kim, S. W.
    Lee, J. H.
    Lee, Y. H.
    Chung, K. H.
    Ryu, J. H.
    Yoon, J. S.
    Kim, J. M.
    Yoo, J. A.
    Youn, T.
    Bae, K. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S488 - S489
  • [35] Impact of atypical antipsychotics on the treatment of patients with schizophrenia in Japan
    Tomita, M.
    Watanabe, K.
    Inagaki, A.
    Den, R.
    Nakagawa, A.
    Takeuchi, H.
    Kikuchi, T.
    Tomita, A.
    Tsunoda, K.
    Kitta, M.
    Yagi, G.
    Kashima, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S279 - S279
  • [36] Effectiveness of atypical antipsychotics for substance use in schizophrenia patients
    Swanson, Jeffrey
    Van Dorn, Richard A.
    Swartz, Marvin S.
    SCHIZOPHRENIA RESEARCH, 2007, 94 (1-3) : 114 - 118
  • [37] Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia
    Yuan Tengfei
    Wang Shaoting
    Le Juan
    Li Yan
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (10): : 1355 - 1361
  • [38] Impact of atypical antipsychotics on the treatment of patients with schizophrenia in Japan
    Tomita, M
    Watanabe, K
    Inagaki, A
    Sawada, N
    Oka, M
    Okuda, R
    Takeuchi, H
    Kikuchi, T
    Tomita, A
    Tsunoda, K
    Yagi, G
    Kashima, H
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S421 - S421
  • [39] Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis
    Bai, Zhihua
    Wang, Guoqiang
    Cai, Shangli
    Ding, Xindi
    Liu, Weiwei
    Huang, Depei
    Shen, Weidi
    Zhang, Juncheng
    Chen, Kui
    Yang, Yuqing
    Zhang, Lili
    Zhao, Xiaochen
    Ouyang, Qiong
    Zhao, Jingping
    Lu, Huafei
    Hao, Wei
    SCHIZOPHRENIA RESEARCH, 2017, 185 : 73 - 79
  • [40] The change of cytokines by atypical antipsychotics (risperidone) in patients with schizophrenia
    Kim, DJ
    Kim, W
    Yoon, SJ
    Go, HJ
    Choi, BM
    Jeun, TY
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S10 - S10
12345